secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001193125-22-276373
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 2.03, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kura Oncology secures $25M equity from BMS and up to $125M debt from Hercules; runway into 2026
--------------------------------------------------------------------------------

- Bristol Myers Squibb invests $25M at $18.25/share for 1.37M shares; BMS appoints member to Global Steering Committee.
- Hercules Capital provides up to $125M term loan; $10M drawn immediately, $15M available at Kura’s discretion.
- Additional $75M in two tranches upon clinical milestones; fourth $25M tranche subject to Hercules approval.
- Loan bears 8.65% interest; interest-only for 24 months extendable to 48 months; matures Nov 2027.
- Proceeds from both transactions, if fully drawn, extend cash runway into 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000119312522276373/0001193125-22-276373-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000119312522276373/d408638d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-276373

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer